3Q venture financing rebounds
This article was originally published in Scrip
Venture capital investment into the biotech drug discovery and development companies in the third quarter returned to historical levels following a strong September. The total amount of money put to work in the global sector during 3Q was about $1.46 billion. In the past five years, with the exception of last year, biotech companies were able to raise between $1.4 billion and $1.5 billion over the summer months. In 2009, the sector barely raised $1.1 billion.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.